LB Pharmaceuticals (LBRX) announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer, CCO. Before joining LB Pharmaceuticals, Pai Panandiker served as Chief Commercial Officer at Neumora Therapeutics (NMRA)
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB Pharmaceuticals Reports Strong Q3 and Strategic Progress
- LB Pharmaceuticals reports Q3 EPS (61c) vs ($39.49) last year
- LB Pharmaceuticals appoints Rawls as SVP of Regulatory Affairs
- Opening Day: Cerebras Systems withdraws IPO filing
- Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential